細(xì)胞名稱：人甲狀腺乳頭狀癌細(xì)胞MDA-T41
產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細(xì)胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運(yùn)輸方式：常溫保溫運(yùn)輸；干冰運(yùn)輸
安全等級(jí)：1
用途限制：僅供科研3類
培養(yǎng)體系：DMEM高糖+10%FBS+1%三抗
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡(jiǎn)介：人甲狀腺乳頭狀癌細(xì)胞MDA-T41取自74歲男性甲狀腺乳頭狀癌患者淋巴結(jié)轉(zhuǎn)移組織。該細(xì)胞源于ATCC.
注釋：倍增時(shí)間38h
基因突變：Heterozygous for BRAF p.Val600Glu(c.1799T>A)(PubMed=23833040;PubMed=25427145;PubMed=30737244).
Heterozygous for RB1 p.Ile831Phe(c.2491A>T)(PubMed=30737244).
Heterozygous for TP53 p.Phe19fs(c.56_65delTTTCAGACCT)and p.Cys176Phe(c.527G>T)(PubMed=30737244).
HLA信息：/
STR信息
Amelogenin X,Y
CSF1PO 11,12
D5S818 9,12
D7S820 8,12
D13S317 9,12
D16S539 12
TH01 6
TPOX 8
vWA 15,16
參考文獻(xiàn)
PubMed=23833040;DOI=10.1210/jc.2013-2383
Landa I.,Ganly I.,Chan T.A.,Mitsutake N.,Matsuse M.,Ibrahimpasic T.,Ghossein R.A.,Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer:higher prevalence in advanced forms of the disease.
J.Clin.Endocrinol.Metab.98:E1562-E1566(2013)
PubMed=25427145;DOI=10.1210/jc.2014-2624
Henderson Y.C.,Ahn S.-H.,Ryu J.,Chen Y.,Williams M.D.,El-Naggar A.K.,Gagea M.,Schweppe R.E.,Haugen B.R.,Lai S.Y.,Clayman G.L.
Development and characterization of six new human papillary thyroid carcinoma cell lines.
J.Clin.Endocrinol.Metab.100:E243-E252(2015)
PubMed=30737244;DOI=10.1158/1078-0432.CCR-18-2953
Landa I.,Pozdeyev N.,Korch C.,Marlow L.A.,Smallridge R.C.,Copland J.A.,Henderson Y.C.,Lai S.Y.,Clayman G.L.,Onoda N.,Tan A.C.,Garcia-Rendueles M.E.R.,Knauf J.A.,Haugen B.R.,Fagin J.A.,Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines:a validated panel for preclinical studies.
Clin.Cancer Res.25:3141-3151(2019)
細(xì)胞操作說(shuō)明書下載：細(xì)胞操作說(shuō)明書
產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細(xì)胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運(yùn)輸方式：常溫保溫運(yùn)輸；干冰運(yùn)輸
安全等級(jí)：1
用途限制：僅供科研3類
培養(yǎng)體系：DMEM高糖+10%FBS+1%三抗
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡(jiǎn)介：人甲狀腺乳頭狀癌細(xì)胞MDA-T41取自74歲男性甲狀腺乳頭狀癌患者淋巴結(jié)轉(zhuǎn)移組織。該細(xì)胞源于ATCC.
注釋：倍增時(shí)間38h
基因突變：Heterozygous for BRAF p.Val600Glu(c.1799T>A)(PubMed=23833040;PubMed=25427145;PubMed=30737244).
Heterozygous for RB1 p.Ile831Phe(c.2491A>T)(PubMed=30737244).
Heterozygous for TP53 p.Phe19fs(c.56_65delTTTCAGACCT)and p.Cys176Phe(c.527G>T)(PubMed=30737244).
HLA信息：/
STR信息
Amelogenin X,Y
CSF1PO 11,12
D5S818 9,12
D7S820 8,12
D13S317 9,12
D16S539 12
TH01 6
TPOX 8
vWA 15,16
參考文獻(xiàn)
PubMed=23833040;DOI=10.1210/jc.2013-2383
Landa I.,Ganly I.,Chan T.A.,Mitsutake N.,Matsuse M.,Ibrahimpasic T.,Ghossein R.A.,Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer:higher prevalence in advanced forms of the disease.
J.Clin.Endocrinol.Metab.98:E1562-E1566(2013)
PubMed=25427145;DOI=10.1210/jc.2014-2624
Henderson Y.C.,Ahn S.-H.,Ryu J.,Chen Y.,Williams M.D.,El-Naggar A.K.,Gagea M.,Schweppe R.E.,Haugen B.R.,Lai S.Y.,Clayman G.L.
Development and characterization of six new human papillary thyroid carcinoma cell lines.
J.Clin.Endocrinol.Metab.100:E243-E252(2015)
PubMed=30737244;DOI=10.1158/1078-0432.CCR-18-2953
Landa I.,Pozdeyev N.,Korch C.,Marlow L.A.,Smallridge R.C.,Copland J.A.,Henderson Y.C.,Lai S.Y.,Clayman G.L.,Onoda N.,Tan A.C.,Garcia-Rendueles M.E.R.,Knauf J.A.,Haugen B.R.,Fagin J.A.,Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines:a validated panel for preclinical studies.
Clin.Cancer Res.25:3141-3151(2019)
細(xì)胞操作說(shuō)明書下載：細(xì)胞操作說(shuō)明書
